| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 6.5 | - | - | 3 |
| Research and development | 21.708 | 25.784 | 28.816 | 29.457 |
| General and administrative | 5.21 | 6.41 | 5.79 | 7.919 |
| Total operating expenses | 26.918 | 32.194 | 34.606 | 37.376 |
| Loss from operations | -20.418 | -32.194 | -34.606 | -34.376 |
| Other income, net | 0.693 | 0.963 | 2.521 | 2.105 |
| Net loss | -19.725 | -31.231 | -32.085 | -32.271 |
| Unrealized gain (loss) on marketable securities, net of tax | 0.003 | -0.013 | -0.023 | 0.457 |
| Comprehensive loss | -19.722 | -31.244 | -32.108 | -31.814 |
| Earnings per share, basic, total | -0.26 | -0.41 | -0.42 | -0.43 |
| Earnings per share, diluted, total | -0.26 | -0.41 | -0.42 | -0.43 |
| Weighted average number of shares outstanding, basic, total | 76,132,337 | 75,993,941 | 75,986,281 | 75,855,949 |
| Weighted average number of shares outstanding, diluted, total | 76,132,337 | 75,993,941 | 75,986,281 | 75,855,949 |
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)